The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

GSK is investing up to $800 million to double the size and capacity of its production site in Marietta, Pennsylvania, the company said Thursday. Through the addition of two new facilities ...

A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster ...

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. The UK ...

GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, announced a landmark investment ...

GSK (GSK) plc announced what it calls its ... manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs, the company stated.

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the ...

GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the company announced Wednesday alongside its ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

MARIETTA, Pa. (WHTM) — A global biopharma company just announced that it will be investing up to $800 million to expand its long-time Lancaster County manufacturing facility. During a press ...